ARCTIC: A randomised, phase IIB trial in previously untreated patients with Chronic Lymphocytic Leukaemia (CLL) to compare fludarabine, cyclophosphamide and rituximab (FCR) with FC, mitoxantrone and low dose rituximab (FCM-miniR)

Registered study from NIHR funded awards. Evidence status: source reported.

Organisation

University of Leeds

Published

2009-01-01

Source reference

07/01/38

Jurisdiction

United Kingdom (funder)

Licence

Open Government Licence v3.0. Contains public sector information from the NIHR Open Data portal; award holders' names not imported.

Contracted organisation: University of Leeds · Programme: Health Technology Assessment · Award: £636,052 · 2009-01-01 to 2014-12-31 · Status: Complete · Found via: a paper's funding metadata

Source: https://fundingawards.nihr.ac.uk/award/07/01/38. Captured 2026-10-30.

Limitations: An NIHR funding award named, by its award number, in a held paper's funding metadata. The award funded research; it does not show which data the research used.